Signaling Pathways and Personalized Therapy in Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: closed (15 May 2023) | Viewed by 2556
Special Issue Editor
2. Karolinska University Hospital, Solna, Sweden
Interests: signaling; RTK; GPCR; ubiquitination; cancer; arrestin; GRK; IGF-1R; targeted therapy insulin; Insulin/IGF axis; metabolic syndrome; molecular pathology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The cellular signaling field has borne witness to multiple paradigm shifts that have important ramifications in our understanding of important physiological processes such as growth, differentiation and aging. Equally importantly, cell signaling anomalies play a dominant role in disease development, including diabetes and cancer. These abnormal signals are often initiated or sustained by plasma membrane receptors, such as tyrosine–kinase receptors (RTK), G protein-coupled receptors (GPCRs), and/or by their intracellular messengers. Different receptor families can utilize common intracellular signaling proteins and pathways; however, biological outcomes are canonically assigned to one or another cell surface receptor family. This multilayered crosstalk between different receptor families controlling the biological outcomes is insufficiently explored or considered for personalized medicine.
This Special Issue of Cells will follow the development of our understanding of cellular signaling pathology, as well as the design of targeted therapy controlling plasma-membrane receptors and their signaling network, with a particular focus on those relating to cancer or metabolic disorders.
Dr. Leonard Girnita
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RTKs
- GPCR
- precision medicine
- biomarkers
- arrestin
- ubiquitination
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
